- Johannes Gerrit Karel Peper,
- Sandra Srbljin,
- Friso Martijn van der Zant,
- Remco Johannes Jacob Knol,
- Maurits Wondergem
Clin Nucl Med 2017 Aug 19. Epub 2017 Aug 19.
From the *Department of Nuclear Medicine and Radiology, Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar; and †Department of Nuclear Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands.
Radioisotope-labeled prostate-specific membrane antigen (PSMA) tracers have been proven accurate for detection of prostate cancer localizations. Uptake of those tracers in other malignant and benign lesions has been reported, including faint accumulation of Ga-PSMA-HBED-CC in adrenal adenoma. A 77-year-old man with prostate carcinoma was scanned with F-DCFPyL, a promising F-labeled PSMA ligand, for prostate-specific antigen progression while on luteinizing hormone-releasing hormone agonist therapy. Read More